OFIX - Orthofix Medical Inc Stock Price, Fair Value and News

13.89USD+0.43 (+3.19%)Market Closed

Market Summary

USD13.89+0.43

Market Closed

3.19%

OFIX Stock Price

View Fullscreen

OFIX RSI Chart

OFIX Valuation

Market Cap

521.3M

Price/Earnings (Trailing)

-4.12

Price/Sales (Trailing)

0.7

EV/EBITDA

-7.6

Price/Free Cashflow

-5.81

OFIX Price/Sales (Trailing)

OFIX Profitability

EBT Margin

-16.53%

Return on Equity

-22.18%

Return on Assets

-13.96%

Free Cashflow Yield

-17.2%

OFIX Fundamentals

OFIX Revenue

Revenue (TTM)

747.3M

Rev. Growth (Yr)

0.36%

Rev. Growth (Qtr)

-12.27%

OFIX Earnings

Earnings (TTM)

-126.5M

Earnings Growth (Yr)

40.89%

Earnings Growth (Qtr)

-62.44%

Breaking Down OFIX Revenue

Last 7 days

6.9%

Last 30 days

-2.4%

Last 90 days

-3.3%

Trailing 12 Months

-25.4%

How does OFIX drawdown profile look like?

OFIX Financial Health

Current Ratio

2.65

Debt/Equity

0.2

Debt/Cashflow

-0.26

OFIX Investor Care

Shares Dilution (1Y)

2.70%

Diluted EPS (TTM)

-3.37

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	747.3M	0	0	0
2023	529.5M	598.4M	668.5M	746.6M
2022	465.3M	462.0M	463.5M	460.7M
2021	407.3M	455.6M	457.0M	464.5M
2020	455.7M	413.0M	410.4M	406.6M
2019	453.4M	457.7M	459.5M	460.0M
2018	439.8M	442.4M	448.9M	453.0M
2017	413.8M	418.7M	425.5M	433.8M
2016	405.4M	408.5M	405.9M	409.8M
2015	392.0M	392.0M	392.2M	396.5M
2014	395.3M	398.7M	407.9M	402.3M
2013	435.3M	421.3M	407.3M	397.6M
2012	464.2M	459.2M	447.7M	440.2M
2011	538.6M	512.4M	490.8M	470.1M
2010	550.3M	555.0M	559.7M	564.4M
2009	0	0	0	545.6M

Get all data in R, Python etc through our Historical Stock Data APIs

GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed Russell 2000 Index

Small Caps and Mid Caps are mostly overlooked by investors as all the focus goes to Magnificent 7. These stocks that are not part of the beauty contest require a deeper look. However, all large cap stocks were once small caps. Grufity's Fair Value model opens up this unverse as it separates high-performing, rewarding stocks from low-performing risky stocks. <b>Russell 2000 stocks that were marked 'Very Cheap' by the model doubled in three years while the index was flat.</b>

Returns of $10,000 invested in:

Very Cheap Stocks: $21,859
Russell 2000 Index: $10,334
Very Expensive Stocks: $8,224

Russell 2000 stocks considered 'Very Cheap' by the model greatly outperformed Russell 2000 index and the 'Very Expensive' bucket over past three years.

Russell 2000 Index

Very Expensive Stocks

Very Cheap Stocks

Try For Just $1.99

Tracking the Latest Insider Buys and Sells of Orthofix Medical Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Apr 15, 2024	cedron jorge andres	acquired	375,002	13.09	28,648	clo
Apr 11, 2024	elting kimberley a.	sold (taxes)	-40,985	13.95	-2,938	president, global orthopedics
Apr 08, 2024	burzik catherine m	sold (taxes)	-675,726	14.23	-47,486	-
Apr 01, 2024	gillespie geoffrey c	sold (taxes)	-984	14.06	-70.00	cao
Apr 01, 2024	elting kimberley a.	sold (taxes)	-28,555	14.06	-2,031	president, global orthopedics
Mar 15, 2024	gillespie geoffrey c	acquired	49,999	13.74	3,639	cao
Feb 01, 2024	elting kimberley a.	sold (taxes)	-28,754	14.27	-2,015	president, global orthopedics
Jan 31, 2024	kummeth charles r.	acquired	115,982	13.89	8,350	-
Jan 31, 2024	finegan michael	acquired	115,982	13.89	8,350	-
Jan 31, 2024	bazaar alan lee	acquired	124,121	13.89	8,936	-

Which funds bought or sold OFIX recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 06, 2024	SG Americas Securities, LLC	reduced	-27.17	-69,000	248,000	-%
May 06, 2024	Quantbot Technologies LP	sold off	-100	-400,733	-	-%
May 06, 2024	HighTower Advisors, LLC	reduced	-22.03	-128,000	669,000	-%
May 06, 2024	NEW YORK LIFE INVESTMENT MANAGEMENT LLC	added	26.01	100,074	380,148	-%
May 03, 2024	GSA CAPITAL PARTNERS LLP	new	-	921,000	921,000	0.07%
May 03, 2024	SIGNATUREFD, LLC	unchanged	-	44.00	624	-%
May 02, 2024	NISA INVESTMENT ADVISORS, LLC	new	-	552	552	-%
May 02, 2024	MUTUAL OF AMERICA CAPITAL MANAGEMENT LLC	added	15.31	497,105	2,550,740	0.03%
May 01, 2024	Mirae Asset Global Investments Co., Ltd.	unchanged	-	33,149	238,126	-%
May 01, 2024	CONCOURSE FINANCIAL GROUP SECURITIES, INC.	sold off	-	-	-	-%

Are Funds Buying or Selling OFIX?

Are funds buying OFIX calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own OFIX

No. of Funds

Unveiling Orthofix Medical Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Apr 22, 2024	engine capital, l.p.	6.9%	2,565,743	SC 13D/A
Feb 14, 2024	armistice capital, llc	9.79%	3,600,000	SC 13G
Feb 13, 2024	vanguard group inc	5.44%	1,999,666	SC 13G/A
Feb 12, 2024	rubric capital management lp	9.97%	3,665,000	SC 13G
Feb 09, 2024	morgan stanley	5.6%	2,057,081	SC 13G
Feb 09, 2024	segall bryant & hamill, llc	0.1%	44,484	SC 13G/A
Jan 08, 2024	blackrock inc.	9.0%	3,317,319	SC 13G/A
Dec 13, 2023	engine capital, l.p.	6.7%	2,479,157	SC 13D/A
Nov 03, 2023	engine capital, l.p.	6.0%	2,196,178	SC 13D
Oct 30, 2023	first light asset management, llc	0.0%	0	SC 13G/A

Recent SEC filings of Orthofix Medical Inc

View All Filings

Date Filed	Form Type	Document
May 07, 2024	10-Q	Quarterly Report
May 07, 2024	8-K	Current Report
Apr 29, 2024	DEF 14A	DEF 14A
Apr 29, 2024	DEFA14A	DEFA14A
Apr 22, 2024	8-K	Current Report
Apr 22, 2024	SC 13D/A	13D - Major Acquisition
Apr 17, 2024	3	Insider Trading
Apr 17, 2024	4	Insider Trading
Apr 16, 2024	S-8	Employee Benefits Plan
Apr 12, 2024	4	Insider Trading

Peers (Alternatives to Orthofix Medical Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
ABT	184.5B	40.3B	-4.60%	-4.35%	32.81	4.58	-2.84%	-3.08%
BDX	68.5B	19.7B	-3.65%	-5.69%	51.42	3.48	4.82%	-17.56%
ALGN	21.6B	3.9B	-9.77%	-6.38%	46.66	5.51	5.72%	46.72%
BAX	18.4B	14.9B	-15.25%	-20.81%	6.95	1.24	2.98%	207.68%
MID-CAP
ATR	9.9B	3.5B	5.58%	23.16%	31.7	2.8	6.16%	35.06%
HSIC	9.1B	12.5B	-1.81%	-10.76%	23.5	0.73	-0.61%	-18.83%
BIO	8.2B	2.7B	-13.87%	-26.12%	-12.81	3.06	-4.68%	82.43%
XRAY	5.9B	3.9B	-12.53%	-31.61%	-62.76	1.49	0.23%	91.03%
AXNX	3.4B	387.1M	-0.62%	22.51%	-215.92	8.89	30.82%	65.57%
PDCO	2.3B	6.6B	-0.84%	-0.80%	12.05	0.36	2.78%	-0.87%
SMALL-CAP
AHCO	1.3B	3.2B	-6.97%	-19.30%	-1.86	0.4	7.94%	-1661.78%
ANIK	421.1M	166.7M	10.85%	9.31%	-5.09	2.53	6.67%	-456.34%
ANGO	245.5M	324.0M	-12.80%	-31.58%	-1.28	0.76	-3.19%	-337.41%
APYX	48.8M	52.3M	-6.00%	-59.48%	-2.61	0.93	17.61%	19.28%
AEMD	3.4M	3.7M	-25.71%	271.43%	-0.28	0.91	5.77%	8.23%

Orthofix Medical Inc News

Latest updates

Orthofix Medical Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Revenue	-12.3%	175,831,000	200,415,000	184,006,000	187,016,000	175,204,000	122,229,000	113,996,000	118,070,000	106,418,000	125,064,000	112,428,000	121,394,000	105,593,000	117,619,000	110,985,000	73,135,000	104,823,000	121,494,000	113,499,000	115,850,000	109,112,000
Gross Profit	-6.9%	127,242,000	136,630,000	119,763,000	119,551,000	110,329,000	89,176,000	83,423,000	86,470,000	78,100,000	91,810,000	84,121,000	93,955,000	79,679,000	88,548,000	84,742,000	49,969,000	81,414,000	95,303,000	88,603,000	90,038,000	85,404,000
Operating Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	91,208,000	107,485,000	89,587,000	89,852,000
S&GA Expenses	2.3%	100,043,000	97,749,000	94,947,000	99,249,000	93,791,000	59,324,000	55,461,000	59,888,000	54,137,000	57,098,000	56,097,000	57,338,000	50,785,000	53,716,000	52,926,000	43,479,000	54,313,000	58,313,000	54,805,000	56,864,000	53,694,000
R&D Expenses	2.9%	19,492,000	18,941,000	18,559,000	19,424,000	23,307,000	13,152,000	11,943,000	12,758,000	11,212,000	13,243,000	12,360,000	13,121,000	10,897,000	10,365,000	9,962,000	8,765,000	9,964,000	8,446,000	7,982,000	8,980,000	9,229,000
EBITDA Margin	23.2%	-0.11	-0.14	-0.14	-0.13	-0.08	0.02	0.02	0.03	0.03	0.03	0.07	0.09	-	-	-	-	-	-	-	-	-
Interest Expenses	-1.3%	-4,558,000	-4,500,000	-1,576,000	-1,266,000	-1,289,000	-229,000	-277,000	-407,000	-375,000	-437,000	-433,000	-550,000	-417,000	-428,000	-731,000	-901,000	-423,000	-508,000	186,000	457,000	-257,000
Income Taxes	580.8%	851,000	125,000	472,000	1,508,000	611,000	75,000	1,344,000	553,000	71,000	23,207,000	-364,000	2,248,000	-207,000	14,948,000	607,000	1,592,000	-20,032,000	-7,456,000	13,656,000	1,219,000	-6,006,000
Earnings Before Taxes	-59.5%	-35,169,000	-22,049,000	-28,385,000	-37,918,000	-60,327,000	-6,987,000	-9,372,000	3,042,000	-4,389,000	-9,605,000	-2,535,000	4,668,000	-6,023,000	5,570,000	5,261,000	-16,832,000	5,633,000	4,230,000	-26,842,000	672,000	-5,109,000
EBT Margin	17.0%	-0.17	-0.20	-0.20	-0.19	-0.14	-0.04	-0.04	-0.03	-0.03	-0.03	0.00	0.02	-	-	-	-	-	-	-	-	-
Net Income	-62.4%	-36,020,000	-22,174,000	-28,857,000	-39,426,000	-60,938,000	-7,062,000	-10,716,000	2,489,000	-4,460,000	-32,812,000	-2,171,000	2,420,000	-5,816,000	-9,378,000	4,654,000	-18,424,000	25,665,000	11,686,000	-40,498,000	-547,000	897,000
Net Income Margin	16.5%	-0.17	-0.20	-0.20	-0.20	-0.14	-0.04	-0.10	-0.08	-0.08	-0.08	-0.03	-0.02	-	-	-	-	-	-	-	-	-
Free Cashflow	-37.1%	-29,138,000	-21,255,000	-21,395,000	-17,867,000	-45,492,000	-2,857,000	-6,391,000	-10,616,000	-13,038,000	5,554,000	3,907,000	-6,847,000	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	-2.1%	906	925	906	901	917	459	450	462	462	477	500	502	514	526	517	596	493	496	476	489	479
Current Assets	-5.1%	399	420	394	399	410	256	247	255	255	270	260	258	263	270	255	344	240	261	238	233	224
Cash Equivalents	-18.6%	27.00	33.00	34.00	38.00	50.00	51.00	52.00	60.00	72.00	88.00	83.00	80.00	95.00	96.00	80.00	173	58.00	70.00	57.00	52.00	47.00
Inventory	-1.4%	219	222	222	222	222	100	100	97.00	89.00	83.00	85.00	82.00	84.00	85.00	83.00	82.00	83.00	82.00	81.00	79.00	79.00
Net PPE	-0.6%	158	159	153	141	137	58.00	58.00	59.00	59.00	59.00	59.00	62.00	62.00	64.00	64.00	65.00	65.00	63.00	63.00	64.00	64.00
Goodwill	0%	195	195	195	192	203	71.00	71.00	71.00	71.00	71.00	83.00	84.00	84.00	84.00	84.00	83.00	11.00	71.00	71.00	71.00	71.00
Liabilities	2.8%	336	327	290	261	253	122	116	120	126	140	136	140	159	169	162	251	138	168	169	141	136
Current Liabilities	-8.8%	151	165	153	142	138	84.00	78.00	81.00	88.00	106	80.00	82.00	99.00	104	93.00	90.00	66.00	85.00	89.00	68.00	64.00
Long Term Debt	23.6%	115	93.00	70.00	51.00	45.00	-	-	-	-	-	-	-	-	-	-	100	-	-	-	-	-
LT Debt, Current	150.0%	3.00	1.00	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
LT Debt, Non Current	-100.0%	-	93.00	70.00	51.00	45.00	-	-	-	-	-	-	-	-	-	-	100	-	-	-	-	-
Shareholder's Equity	-4.7%	570	599	615	640	664	337	334	342	336	337	365	362	355	357	355	345	355	328	306	348	344
Retained Earnings	-24.0%	-186	-150	-127	-99.11	-59.69	1.00	8.00	19.00	17.00	21.00	54.00	56.00	54.00	59.00	69.00	64.00	83.00	58.00	46.00	87.00	87.00
Additional Paid-In Capital	0.9%	753	746	742	736	721	335	328	324	318	314	308	303	298	292	285	282	276	271	263	258	253
Shares Outstanding	0.7%	37.00	37.00	37.00	37.00	36.00	20.00	20.00	20.00	20.00	20.00	20.00	20.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	-	663	-	-	-	471	-	-	-	789	-	-	-	615	-	-	-	996	-

Cashflow (Last 12 Months)

(In Thousands)

Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	-177.8%	-18,595	-6,694	477	-5,516	-34,020	2,348	-1,264	-4,913	-7,709	11,779	6,432	-2,177	2,441	22,291	21,887	17,630	12,464	11,943	11,746	9,383	-1,039
Share Based Compensation	177.9%	8,800	3,167	6,274	13,246	13,020	4,922	4,729	4,460	4,332	3,962	3,842	3,907	3,721	3,808	3,841	4,699	3,859	4,162	5,844	5,849	5,685
Cashflow From Investing	27.8%	-10,867	-15,053	-22,343	-12,819	17,084	-5,900	-5,473	-7,494	-5,667	-8,982	-4,239	-5,011	-4,781	-9,390	-14,372	-4,388	-24,184	-1,643	-4,543	-5,422	-11,316
Cashflow From Financing	-15.1%	21,453	25,280	18,251	5,808	15,983	1,498	-252	909	-2,233	2,052	855	-7,638	1,110	2,662	-101,335	101,603	315	1,922	-1,029	-1,185	-10,396

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

OFIX Income Statement

2023-12-31

Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Income Statement [Abstract]
Net sales	$ 746,641	$ 460,713	$ 464,479
Cost of sales	260,368	123,544	114,914
Gross profit	486,273	337,169	349,565
Sales and marketing	385,736	228,810	221,318
General and administrative	144,659	79,966	69,353
Research and development	80,231	49,065	49,621
Acquisition-related amortization and remeasurement (Note 17)	14,757	(7,404)	17,588
Operating loss	(139,110)	(13,268)	(8,315)
Interest expense, net	(8,631)	(1,288)	(1,837)
Other expense, net	(938)	(3,150)	(3,343)
Income (loss) before income taxes	(148,679)	(17,706)	(13,495)
Income tax expense	(2,716)	(2,043)	(24,884)
Net loss	$ (151,395)	$ (19,749)	$ (38,379)
Net loss per common share:
Basic	$ (4.12)	$ (0.98)	$ (1.95)
Diluted	$ (4.12)	$ (0.98)	$ (1.95)
Weighted average number of common shares:
Basic	36,729,258	20,053,548	19,690,593
Diluted	36,729,258	20,053,548	19,690,593
Other comprehensive income (loss), before tax
Unrealized gain (loss) on debt securities	$ (1,334)	$ 395	$ (942)
Currency translation adjustment	1,417	(1,771)	(2,544)
Other comprehensive income (loss), before tax	83	(1,376)	(3,486)
Income tax benefit (expense) related to items of other comprehensive income (loss)			234
Other comprehensive income (loss), net of tax	83	(1,376)	(3,252)
Comprehensive loss	$ (151,312)	$ (21,125)	$ (41,631)

OFIX Balance Sheet

2023-12-31

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets
Cash and cash equivalents	$ 33,107	$ 50,700
Restricted cash	4,650
Accounts receivable, net of allowances of $7,130 and $6,419, respectively	128,098	82,857
Inventories	222,166	100,150
Prepaid expenses and other current assets	32,422	22,283
Total current assets	420,443	255,990
Property, plant and equipment net	159,060	58,229
Intangible assets, net	117,490	47,388
Goodwill	194,934	71,317
Other long-term assets	33,388	25,705
Total assets	925,315	458,629
Current liabilities
Accounts payable	58,357	27,598
Current portion of long-term debt	1,250
Current portion of finance lease liability	708	652
Other current liabilities	104,908	55,374
Total current liabilities	165,223	83,624
Long-term debt	93,107
Long-term portion of finance lease liability	18,532	19,239
Other long-term liabilities	49,723	18,906
Total liabilities	326,585	121,769
Contingencies (Note 13)
Shareholders’ equity
Common shares $0.10 par value; 100,000 shares authorized; 37,165 and 20,162 issued and outstanding as of December 31, 2023 and 2022, respectively	3,717	2,016
Additional paid-in capital	746,450	334,969
Retained earnings (accumulated deficit)	(150,144)	1,251
Accumulated other comprehensive loss	(1,293)	(1,376)
Total shareholders’ equity	598,730	336,860
Total liabilities and shareholders’ equity	$ 925,315	$ 458,629

About Orthofix Medical Inc

Orthofix Medical Inc. operates spine and orthopedics company in the United States, Italy, Germany, France, the United Kingdom, Brazil, and internationally. It operates through Global Spine and Global Orthopedics segments. The Global Spine segment comprises the bone growth therapies products, which manufactures and distributes bone growth stimulator devices for enhance of bone fusion including adjunctive and noninvasive treatment of cervical and lumbar spine as well as a therapeutic treatment for non-spine; the spinal implants products designs, develops, and markets a portfolio of motion preservation and fixation implant products, which are used in surgical procedures of the spine; and the biological products, such as regenerative products and tissue forms which allow physicians to treat a variety of spinal and orthopedic conditions. Global Orthopedics segment offers products and solutions that allow physicians to treat a variety of orthopedic conditions unrelated to the spine, which design, develop, and market the orthopedic products used in fracture repair, deformity correction, and bone reconstruction procedures. It sells its products through distributors, sales representatives, hospitals, and healthcare providers. The company was formerly known as Orthofix International N.V. and changed its name to Orthofix Medical Inc. in 2018. Orthofix Medical Inc. was founded in 1987 and is headquartered in Lewisville, Texas.

CEO	Mr. Keith C. Valentine
WEBSITE	orthofix.com
INDUSTRY	Medical Instruments & Supplies
EMPLOYEES	1092

Orthofix Medical Inc Frequently Asked Questions

What is the ticker symbol for Orthofix Medical Inc? What does OFIX stand for in stocks?

OFIX is the stock ticker symbol of Orthofix Medical Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Orthofix Medical Inc (OFIX)?

As of Tue May 07 2024, market cap of Orthofix Medical Inc is 519.58 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of OFIX stock?

You can check OFIX's fair value in chart for subscribers.

What is the fair value of OFIX stock?

You can check OFIX's fair value in chart for subscribers. The fair value of Orthofix Medical Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Orthofix Medical Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for OFIX so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Orthofix Medical Inc a good stock to buy?

The fair value guage provides a quick view whether OFIX is over valued or under valued. Whether Orthofix Medical Inc is cheap or expensive depends on the assumptions which impact Orthofix Medical Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for OFIX.

What is Orthofix Medical Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Tue May 07 2024, OFIX's PE ratio (Price to Earnings) is -3.43 and Price to Sales (PS) ratio is 0.7. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. OFIX PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Orthofix Medical Inc's stock?

In the past 10 years, Orthofix Medical Inc has provided -0.078 (multiply by 100 for percentage) rate of return.